Cgrp receptor antagonists

Abstract

Compounds of Formula I: (wherein variables A 1 , A 2 , A 3 , ring-B, m, n, J, E 1 , E 2 , E 3 , R 5 , R PG and Y are as described herein), which are useful as antagonists of CGRP receptors, and useful in the treatment or prevention of diseases in which CGRP receptors are involved, such as headache, and in particular migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising the compounds of formula (I) and the use of these compounds and compositions in the prevention or treatment of diseases in which CGRP receptors are involved.

1 - 17 . (canceled) 
     
     
         18 . The following compounds: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         19 . A compound of formula (VA) 
       
         
           
           
               
               
           
         
       
       wherein R b  is selected from the group consisting of 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, or the compound of formula (V) is a compound of formula (VB) 
       
         
           
           
               
               
           
         
       
       wherein R b  is 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         20 . A compound of formula: 
       
         
           
           
               
               
           
         
       
       wherein R b  is 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         21 . A pharmaceutical composition which comprises an inert carrier and the compound of  claim 19 , or a pharmaceutically acceptable salt thereof. 
     
     
         22 . A method of treating headache in a mammalian patient in need of such treatment, which comprises administering to the patient a therapeutically effective amount of the compound of claim  1 , or a pharmaceutically acceptable salt thereof. 
     
     
         23 . The method of  claim 22 , wherein the headache is migraine headache or cluster headache. 
     
     
         24 - 25 . (canceled)